| Disease Domain | Count | 
|---|---|
| Neoplasms | 9 | 
| Nervous System Diseases | 1 | 
| Endocrinology and Metabolic Disease | 1 | 
| Top 5 Drug Type | Count | 
|---|---|
| Small molecule drug | 31 | 
| Diagnostic radiopharmaceuticals | 1 | 
| Target | 
| Mechanism NOX inhibitors [+1]  | 
| Active Org. | 
| Originator Org. | 
| Active Indication | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target | 
| Mechanism KRAS G12D modulators | 
| Active Org. | 
| Originator Org. | 
| Active Indication | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target | 
| Mechanism BRD9 modulators | 
| Active Org. | 
| Originator Org.- | 
| Active Indication | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Start Date01 Aug 2025 | 
| Sponsor / Collaborator | 
| Start Date01 Jul 2025 | 
| Sponsor / Collaborator | 
| Start Date01 Feb 2025 | 
| Sponsor / Collaborator | 

| Drug(Targets) | Indications | Global Highest Phase | 
|---|---|---|
| BRD9 modulators(University of Salerno)-compounds 12(  BRD9 ) | Neoplasms More | Preclinical | 
| Compound 3 (China Pharmaceutical University)(  KRAS G12D ) | Inflammation More | Preclinical | 
| BRD9 modulators(University of Salerno)-compounds 5(  BRD9 ) | Neoplasms More | Preclinical | 
| BRD9 modulators(University of Salerno)-compounds 11(  BRD9 ) | Neoplasms More | Preclinical | 
| BRD9 modulators(University of Salerno)-compounds 19(  BRD9 ) | Neoplasms More | Preclinical | 





